According to Thelansis the global Crohn’s disease (CD) market was estimated at ~$6,825 MN in 2020 and expected to reach at ~$ 12,346 MN by the end of 2030 (10 years of markets forecasting). They attribute the high growth to the launches of biologics and biosimilars of Humira, Cimzia, and Tysabri and increased uptake of Remicade and Entocort.
According to Thelansis, globally ~ 2.4 MN patients are being diagnosed with Crohn’s disease (CD) in 2020 among which 8MM countries are comprised of ~75% of the total yearly reported cases. Considering the country level perspective the USA and EU5 are contributing around ~73% of the total diagnosed patient pool, however, in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA, EU5 and Japan attributed to the early screening programs and the diagnosis of the patients in the early stages of the disease.
Molecular epidemiology study of specific biomarker mutations across country level has been given a clear understanding on patient pool across different biomarker targets (TNF-alpha, CARD15, IBD5, ATG16L1, IRGM, interleukins, and another inflammatory cytokine)
Current therapy: One goal of medical therapy is to suppress the inflammatory response, thereby allowing the intestinal tissue to heal, and also relieving symptoms of fever, diarrhea, and abdominal pain. Medications are also used to reduce the frequency of disease flares.
There are five categories of drugs used to treat Crohn’s disease:
• Aminosalicylates (5-ASA), • Corticosteroids, • Antibiotics, • Immune modifiers, • Biologic therapies (Infliximab, Adalimumab, Natalizumab, Certolizumab pegol, etc.), • Others
Emerging therapies: As per Thelansis, based on tumor mutation evidence some of key player are into developing therapies for the treatment of Crohn’s disease such as: Celgene, Gilead Sciences, Otsuka, Galapagos, J&J, AbbVie, Boehringer Ingelheim, Allergan, UCB, Elan Pharmaceuticals, Biogen, Shire, Mitsubishi, Fast Forward, Roche, Amgen, Qu Biologics, AstraZeneca, Theravance Biopharma, GSK, Valeant Pharmaceuticals, Novartis, Landos Biopharma, Eli Lilly, Reistone Biopharma, Provention Bio, Pfizer, BMS
The annual cost of therapy:
According to Thelansis’s literature review, for patients with CD, the yearly cost burden ranges from $2,952 to $20,928 includes all hospitalization and non-hospitalization costs. v Pharmaceutical therapy claims accounted for the largest proportion of direct costs (41.3%) among which TNF alpha was the most costly medication; approximately 10% of patients with CD had at least 2 claims for infliximab infusions. Hospitalization and outpatient services accounted for around 32.5% and 34.1%, respectively.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published report across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial result throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.